News

Empty gabapentin capsules spur recall


 

References

Following the discovery of capsules found to be empty, Aurobindo Pharma USA has initiated a recall of the epilepsy treatment gabapentin, the company announced Nov. 21.

The company is voluntarily recalling lot GESB14011-A of 100-count bottles of 300 mg gabapentin, which have an expiration date of December 2015. The product also is used to manage postherpetic neuralgia.

The Food and Drug Administration noted that the empty capsules could result in missed doses, potentially resulting in no effect, short-term efficacy reduction, short-term withdrawal effect, or status epilepticus that could be life threatening.

gtwachtman@frontlinemedcom.com

Recommended Reading

Topiramate approved for migraine prevention in adolescents
MDedge Pediatrics
Childhood sports knee injuries carry heavy burden
MDedge Pediatrics
AUDIO: Reduction in perceived stress triggers migraine
MDedge Pediatrics
Changing marijuana laws pose health challenges
MDedge Pediatrics
Opioid prescribing varies widely across the country
MDedge Pediatrics
J-Tip syringe cuts venipuncture pain in young kids
MDedge Pediatrics
VIDEO: Dr. Fauci: What you need to know about chikungunya
MDedge Pediatrics
Chikungunya vaccine safe, immunogenic in phase I trial
MDedge Pediatrics
NHLBI expert panel issues guideline on sickle cell disease
MDedge Pediatrics
Topiramate
MDedge Pediatrics